Drugs Medical Pharma

BioNTech, Duality Biologics sign $1.5 billion pact for cancer drugs

HQ Team April 3, 2023: BioNTech SE and Duality Biologics (Suzhou) have signed a $1.5 billion deal to develop and commercialise two cancer.

Read More
Drugs Pharma

Novartis AG stops breast cancer trial as it achieves early success

Novartis AG, the world's fourth-largest pharmaceutical company by revenue, announced its Kisqali drug reduced breast cancer recurrence when diagnosed at an early stage.

Read More
Drugs Medical Pharma

BioNTech in one million euro push for research on drugs

BioNTech, a Germany-based biotechnology company, is expected to spend between 2.4 million euros and 2.6 million euros on research this year compared with.

Read More
Drugs Medical Pharma

BioNTech, OncoC4 in pact to develop drug for solid tumours

BioNTech, a German immunotherapy company, announced a strategic pact with OncoC4, a private firm, to develop and commercialise a drug to treat solid tumours.

Read More
Drugs Medical Pharma

Merck says trial hypertension drug enhances patients’ walk time

Merck announced its experimental trial on patients with pulmonary arterial hypertension had led to an extension in walking distance and reduced exacerbating the.

Read More
Drugs Pharma

FDA rejects Cytokinetics heart disease trial drug

Cytokinetics, a US-based biopharmaceutical company, announced the FDA had rejected its new drug application for approving a trial drug to treat heart problems.

Read More
Drugs Pharma

Eiasi files market authorization for Alzheimer’s drug in Japan

Eiasi Co., a Japanese pharmaceutical company, has submitted a marketing authorization application for a drug, lacanemab, to treat Alzheimer's disease.

Read More
Drugs Medical Pharma

China’s Everest starts first phase operations to make mRNA vaccines

Everest Medicines, a Chinese biopharmaceutical company, announced the start of operations in the first phase at a global manufacturing site to make an.

Read More
Drugs Pharma

Merck acquires Imago BioSciences for $1.35 billion

Merck, a US multinational pharmaceutical company, announced it would acquire Imago BioSciences for $1.35 billion.

Read More